E. Ohman J or Asset Management AB Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

E. Ohman J or Asset Management AB cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,781 shares of the company's stock after selling 12,200 shares during the quarter. E. Ohman J or Asset Management AB owned approximately 0.09% of Tarsus Pharmaceuticals worth $1,926,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TARS. Allspring Global Investments Holdings LLC boosted its position in shares of Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after acquiring an additional 29,465 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Creative Planning purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at approximately $362,000. Vestal Point Capital LP acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $7,565,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $3,590,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TARS has been the topic of a number of recent analyst reports. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Barclays raised their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a report on Monday, January 27th. Finally, The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded down $0.37 during midday trading on Friday, hitting $52.95. 620,699 shares of the company's stock were exchanged, compared to its average volume of 545,759. The firm's 50 day simple moving average is $52.01 and its 200 day simple moving average is $40.69. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -13.90 and a beta of 1.01.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.